Related Experiment Video
Updated: Jun 13, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy
Sara Trifari1, Francesco Marangoni, Samantha Scaramuzza
1San Raffaele-Telethon Institute for Gene Therapy (HSR-TIGET), Via Olgettina 58, 20132 Milan, Italy. s.trifari@hsr.it
Abstract:
Gene therapy, based on the transplantation of genetically corrected autologous hematopoietic stem cells (HSCs), has proven to be an effective therapeutic approach as an alternative to allogenic HSC transplantation for the cure of severe combined immunodeficiencies (SCID). In this article, the recent preclinical studies aiming towards gene therapy trials for the Wiskott-Aldrich syndrome (WAS), a life-threatening immunodeficiency characterized by infections, hemorrhages, autoimmune disorders and lymphomas, will be reviewed. An update of the safety and efficacy data obtained in studies performed in murine disease models and in cells from WAS patients will be presented. Based on these data and on the clinical results of the recent trials for SCID, the most critical issues regarding the implementation of a gene therapy approach for WAS will be discussed.
Related Concept Videos
iPS Cell Differentiation
Gene Therapy
Gene Therapy
Pleiotropy
Pharmacogenomics: Identification of New Drug Targets
EPS and iPS Cells in Disease Research
